Evidence map›Paper›PMID 31849649›Full record

ArticleFrontiers in pharmacology2019

European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development-Be Prepared.

Tim Hardman, Henri Caplain, Sylvie Rottey, Desiree Douglas, Steffan Stringer, Hildegard Sourgens

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tim HardmanAssociation for Human Pharmacology in the Pharmaceutical Industry (AHPPI), Richmond, United Kingdom.
Henri CaplainAssociation Francaise de Pharmacologie Translationelle (AFPT), Paris, France.
Sylvie RotteyBelgian Association of Phase-1 Units (BAPU), Brussels, Belgium.
Desiree DouglasAssociation for Human Pharmacology in the Pharmaceutical Industry (AHPPI), Richmond, United Kingdom.
Steffan StringerAssociation for Human Pharmacology in the Pharmaceutical Industry (AHPPI), Richmond, United Kingdom.
Hildegard SourgensAssociation for Applied Human Pharmacology (AGAH), Hamburg, Germany.
Association of the British Pharmaceutical Industry · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The second biennial conference of the European Federation for Exploratory Medicines Development (EUFEMED) was the result of a continued effort of EUFEMED to gather all stakeholders of exploratory clinical drug development to evaluate and discuss recent developments in the field. The conference focused on how the landscape around early clinical development is changing and how clinical pharmacologists might prepare for these changes. A preconference workshop gave consideration to the impact that modeling and simulation, including physiology-based pharmacokinetic strategies, is having on the practice of clinical development. A second workshop looked at the challenges introduced by biological agents. The keynote address explored the potential role of virtual trials in early medicines development with emphasis on how models can help to understand and inform the drug development process. Presentations that followed covered a broad range of subjects including the potential impact of digital support on study performance in early phase development, extending from recruitment to remote data collection, lay person summaries, data transparency, and ethical considerations for trials in healthy subjects. The second day of the conference focused on future regulatory challenges in the field of early clinical development (including Brexit) and how to prepare for changes in the landscape. Subjects covered included new approaches and designs in oncology, the introduction of more complex study designs and digital biomarkers. Presentations given by invited speakers are published at https://www.eufemed.eu/download-presentations-of-the-lyon-conference-2019/.

Indexed as

conference reportearly phase clinical drug developmentEUFEMEDpharmacokineticsthe European Federation for Exploratory Medicines Development

Identifiers

PMID31849649
PMCPMC6897335
OpenAlexW2990955724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.